Compare Becton Dickinson and Co (BDX) vs Citigroup Inc. (C) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Citigroup Inc. — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Citigroup Inc. trades at $134.32 (market cap $227.30B). The key difference: Citigroup Inc. is far larger — about 5.5× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | C | |
|---|---|---|
Market Cap | $41.51B | $227.30B |
Sector | Health | Financials |
52-Week High | $185.39 | $145.67 |
52-Week Low | $135.49 | $90.02 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Citigroup (C) trades at $140.70, up 0.07% on the day, with a bullish technical outlook and strong Q2 2026 earnings beats. Revenue growth accelerated to $85.21B in 2025, with net income margin improving to 16.78%. The stock is supported by positive analyst sentiment, with 59% recommending Buy and a consensus price target of $157.25. Recent news highlights robust trading and investment banking performance driving the best quarterly results in a decade.
The outlook remains positive given earnings momentum and strategic investments, but risks include volatile cash flows from operations and high leverage. Upside potential exists if the company sustains revenue growth and improves operational efficiency, though macroeconomic sensitivity and competitive pressures could limit gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Citigroup Inc.
Citigroup Inc. is a diversified financial services holding company that provides a broad range of financial services to consumer and corporate customers. The Company services include investment banking, retail brokerage, corporate banking, and cash management products and services. Citigroup serves customers globally.
Read more on C →
